Profitability
This table compares ObsEva and Avenue Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ObsEva | N/A | -416.36% | -92.01% |
| Avenue Therapeutics | N/A | -471.57% | -296.50% |
Volatility & Risk
ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.51, indicating that its stock price is 151% less volatile than the S&P 500.
Valuation & Earnings
This table compares ObsEva and Avenue Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ObsEva | N/A | N/A | -$58.38 million | ($0.92) | N/A |
| Avenue Therapeutics | N/A | N/A | -$10.38 million | $0.76 | 0.82 |
ObsEva is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
17.5% of ObsEva shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 14.4% of ObsEva shares are owned by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
ObsEva beats Avenue Therapeutics on 5 of the 8 factors compared between the two stocks.
About ObsEva
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.
About Avenue Therapeutics
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.
